Our data were concordant with a recent study showing the administration of anti-TIM-3 mAb had a tumor-suppressing effect in several transplantable and chemical carcinogen-induced fibrosarcoma tumor models via CD4+ and CD8+ T-cell- and IFN-γ-dependent mechanisms [16,35]. This evidence concerns the gene CD8A and fibrosarcoma.